GCP
LGND icon

GSA Capital Partners’s Ligand Pharmaceuticals LGND Stock Holding History

GSA Capital Partners’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,170
Closed -$875K – 1892
2024
Q4 		$875K Buy
+8,170
New +$924K 0.06% 496
2024
Q3 		– Sell
-5,939
Closed -$500K – 1840
2024
Q2 		$500K Buy
5,939
+1,419
+31% +$113K 0.04% 965
2024
Q1 		$330K Buy
+4,520
New +$333K 0.03% 1158
2023
Q3 		– Sell
-3,785
Closed -$273K – 1730
2023
Q2 		$273K Buy
+3,785
New +$284K 0.03% 1103
2023
Q1 		– Sell
-20,835
Closed -$1.39M – 1722
2022
Q4 		$1.39M Buy
+20,835
New +$1.35M 0.17% 83
2020
Q4 		– Sell
-10,387
Closed -$618K – 1433
2020
Q3 		$618K Buy
+10,387
New +$709K 0.1% 281
2020
Q1 		– Sell
-8,499
Closed -$553K – 1322
2019
Q4 		$553K Buy
8,499
+3,049
+56% +$204K 0.06% 587
2019
Q3 		$338K Sell
5,450
-11,297
-67% -$709K 0.05% 806
2019
Q2 		$1.19M Buy
16,747
+4,800
+40% +$354K 0.13% 167
2019
Q1 		$937K Sell
11,947
-2,693
-18% -$204K 0.09% 323
2018
Q4 		$1.24M Buy
14,640
+5,625
+62% +$600K 0.14% 142
2018
Q3 		$1.54M Sell
9,015
-2,947
-25% -$444K 0.09% 392
2018
Q2 		$1.55M Sell
11,962
-12,245
-51% -$1.37M 0.08% 430
2018
Q1 		$2.49M Buy
24,207
+2,086
+9% +$206K 0.13% 182
2017
Q4 		$1.89M Buy
+22,121
New +$1.92M 0.12% 255
2016
Q2 		– Sell
-14,595
Closed -$975K – 1819
2016
Q1 		$975K Buy
14,595
+231
+2% +$14K 0.06% 554
2015
Q4 		$972K Sell
14,364
-5,834
-29% -$360K 0.05% 729
2015
Q3 		$1.08M Sell
20,198
-10,259
-34% -$622K 0.05% 581
2015
Q2 		$1.92M Buy
30,457
+16,671
+121% +$910K 0.07% 407
2015
Q1 		$663K Buy
+13,786
New +$528K 0.03% 1191

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GSA Capital Partners's LGND Position: Q1 2025 in Review

GSA Capital Partners sold out of Ligand Pharmaceuticals (LGND) in Q1 2025, closing a stake of 8,170 shares — an estimated $875K sold.

GSA Capital Partners first reported a position in LGND in Q1 2015 and held it in 20 quarters. The position peaked at $2.49M in Q1 2018. 262 funds tracked by Wall St. Rank hold LGND as of Q1 2025.

  • GSA Capital Partners reported no remaining Ligand Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • GSA Capital Partners sold 8,170 Ligand Pharmaceuticals shares in Q1 2025, an estimated $875K.
  • GSA Capital Partners first reported a position in Ligand Pharmaceuticals in Q1 2015 and held it in 20 quarters.
  • GSA Capital Partners's Ligand Pharmaceuticals position peaked at $2.49M in Q1 2018.
  • 262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2025.

Based on GSA Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.